Table 1.

HER2 is amplified in all PAM50 subtypes, and enriched in HER2E

Subtype	TCGA (n = 106)	Metabric (n = 133)	USO1062 (n = 79)
HER2E	48 (45%)	71 (53%)	30 (38%)
Luminal A	19 (18%)	14 (11%)	26 (33%)
Luminal B	32 (30%)	27 (20%)	17 (21%)
Basal-like	7 (7%)	21 (16%)	6 (8%)

Number and percentage of human epidermal growth factor receptor 2 amplified (HER2A) tumors across the prediction analysis of microarray 50 (PAM50) subtypes in The Cancer Genome Atlas (TCGA), Metabric and the USO1062 clinical trial. HER2E HER2-enriched